Mimetas US Inc.
Gaithersburg, MD Part of BHI Management Inc.
- UEI
- QGP7JLTGMAK9
- CAGE
- 757F3
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
-
- 541714 Research and Development in Biotechnology (except Nanobiotechnology) Primary
- 325320 Pesticide and Other Agricultural Chemical Manufacturing
- 325411 Medicinal and Botanical Manufacturing
- 325412 Pharmaceutical Preparation Manufacturing
- 325413 In-Vitro Diagnostic Substance Manufacturing
- 325414 Biological Product (except Diagnostic) Manufacturing
- 541380 Testing Laboratories and Services
- 541614 Process, Physical Distribution, and Logistics Consulting Services
- Corporate family
-
-
BHI Management Inc.
Parent
XUDKKZPGFMR6
- Mimetas US Inc. QGP7JLTGMAK9
-
BHI Management Inc.
Parent
XUDKKZPGFMR6
- SAM.gov registration date
- Physical address
- 704 Quince Orchard Rd #260, Gaithersburg, MD 20878, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of the nephroplate: a high-throughput kidney-on-a-chip platform for identifying chronic kidney disease… | National Institute of Diabetes and Digestive and Kidney Diseases | $3,500,000 | |
| Development of the nephroplate: a high-throughput kidney-on-a-chip platform for identifying chronic kidney disease… | National Institute of Diabetes and Digestive and Kidney Diseases | $236,779 | |
| Topic #355 - sbir phase II - a 3D perfusable platform for HTS across diverse racial/ethnic cancer SPE | National Cancer Institute | $2,000,000 | |
| Development and evaluation of the hepaplate IPS: a high throughput organ-on-achip IPS hepatotoxicty screening platform | National Institute on Drug Abuse | $1,500,000 | |
| Sbir topic 355: a 3D perfusable platform for HTS across diverse racial/ethnic cancer specimens to generate racially… | National Cancer Institute | $297,962 |
About Mimetas US Inc.
Mimetas US Inc. is a self-certified small disadvantaged business and for-profit organization based in Montgomery Village, Maryland. It provides advanced 3D cell culture and organ-on-a-chip technologies, including high-throughput screening platforms for disease modeling and drug discovery applications.
Through federal contracts, Mimetas US Inc. has received funding from agencies like the National Institutes of Health (NIH) and the National Cancer Institute. One notable award is a $2 million Small Business Innovation Research (SBIR) Phase II contract from NIH's National Cancer Institute for developing a 3D perfusable platform for high-throughput screening across diverse racial/ethnic cancer specimens. This contract aimed to create a system for evaluating cancer treatments on patient-derived tumor samples, enabling personalized medicine approaches.
Mimetas US Inc. has also received several federal grants, primarily from the NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). A substantial $3.5 million project grant supports the development of the NephroPlate, a high-throughput kidney-on-a-chip platform for identifying chronic kidney disease therapies. This project involves modeling various glomerular diseases, such as Alport syndrome, membranous nephropathy, diabetic nephropathy, and APOL1 nephropathy, to study disease mechanisms and screen potential treatments. Another $236,779 grant from NIDDK funded the initial phase of the NephroPlate project. These grants highlight Mimetas US Inc.'s expertise in developing advanced 3D cell culture models and organ-on-a-chip systems for disease modeling and drug discovery applications, with a focus on kidney diseases.
Contract vehicles
Quick answers
What is Mimetas US Inc.'s UEI?
Mimetas US Inc.'s Unique Entity ID (UEI) in SAM.gov is QGP7JLTGMAK9.
What is Mimetas US Inc.'s CAGE code?
Mimetas US Inc.'s CAGE code is 757F3.
What is Mimetas US Inc.'s primary NAICS code?
Mimetas US Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Mimetas US Inc. located?
Mimetas US Inc.'s physical address in SAM.gov is 704 Quince Orchard Rd #260, Gaithersburg, MD 20878, USA.
Is Mimetas US Inc. registered in SAM.gov?
Yes. Mimetas US Inc.'s SAM.gov registration is active through November 18, 2026.
Who is Mimetas US Inc.'s parent company?
Mimetas US Inc. is part of BHI Management Inc.
Which contract vehicles does Mimetas US Inc. hold?
Mimetas US Inc. holds a place on 1 federal contract vehicle: Pre-Clinical Models of Infectious Diseases.
What is Mimetas US Inc.'s most recent federal award?
Mimetas US Inc.'s most recent federal grant award is Development of the nephroplate: a high-throughput kidney-on-a-chip platform for identifying chronic kidney disease… (R44DK127659), from National Institute of Diabetes and Digestive and Kidney Diseases, on September 28, 2020.
On GovTribe
See Mimetas US Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors